Reagenti e strumenti per immunologia, biologia cellulare e biologia molecolare

Entinostat [209783-80-2]

Stampa

Cat# HY-12163-5mg

Size : 5mg

Marca : MedChemExpress

Richiedere ulteriori informazioni

Description

Entinostat is an oral and selective class I HDAC inhibitor, with IC₅₀s of 243 nM, 453 nM, and 248 nM for HDAC1, HDAC2, and HDAC3, respectively.

IC₅₀ & Target^[1]

HDAC1

243 nM (IC₅₀)

HDAC3

248 nM (IC₅₀)

HDAC2

453 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	3.67 μM Compound: MS275	Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
A-375	IC₅₀	3.67 μM Compound: MS275	Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A375 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A2780	CC₅₀	3000 nM Compound: 3, MS-275, SNDX-275	Antiproliferative activity against human A2780 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human A2780 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
A2780	IC₅₀	3000 nM Compound: 4, MS-275	Antiproliferative activity against human A2780 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human A2780 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
A2780	IC₅₀	5.89 μM Compound: Entinostat	Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay Antiproliferative activity against human A2780 cells after 48 hrs by MTT assay	[PMID: 28340413]
A549	CC₅₀	1200 nM Compound: 3, MS-275, SNDX-275	Antiproliferative activity against human P53 expressing A549 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53 expressing A549 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
A549	GI₅₀	18.37 μM Compound: MS-275	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28629630]
A549	GI₅₀	5.76 μM Compound: 6; MS-275	Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human A549 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
A549	IC₅₀	1.48 μM Compound: 5; MS-275	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
A549	IC₅₀	1.48 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay Antiproliferative activity against human A549 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
A549	IC₅₀	1.71 μM Compound: 2; MS-275	Antiproliferative activity against human A549 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based CCK-8 assay Antiproliferative activity against human A549 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based CCK-8 assay	[PMID: 34097389]
A549	IC₅₀	1200 nM Compound: 4, MS-275	Antiproliferative activity against human A549 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human A549 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
A549	IC₅₀	1200 nM Compound: 6; MS-275	Growth inhibition of human A549 cells after 48 hrs by SRB assay Growth inhibition of human A549 cells after 48 hrs by SRB assay	[PMID: 30476825]
A549	IC₅₀	2.25 μM Compound: MS-275	Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human A549 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
A549	IC₅₀	3.11 μM Compound: Entinostat	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 28340413]
A549	IC₅₀	3.134 μM Compound: MS-275	Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 26140961]
A549	IC₅₀	3.58 μM Compound: 1g, MS-275	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 18247554]
A549	IC₅₀	3.58 μM Compound: MS-275 (4)	Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay	[PMID: 14667227]
A549	IC₅₀	4.9 μM Compound: MS-275	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
A549	IC₅₀	5.41 μM Compound: Entinostat	Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
A549	IC₅₀	5.41 μM Compound: MS-275	Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human A549 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
A549	IC₅₀	7.15 μM Compound: MS275	Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
A549	IC₅₀	8 μM Compound: 4 (MS-275)	Inhibitory concentration against lung A549 cell line Inhibitory concentration against lung A549 cell line	[PMID: 12593661]
A549	IC₅₀	< 0.1 μM Compound: MS-275	Antiproliferative activity against human A549 cells after 48 hrs by MTT assay Antiproliferative activity against human A549 cells after 48 hrs by MTT assay	[PMID: 22705022]
ACHN	IC₅₀	2.4 μM Compound: MS-275	Antiproliferative activity against human ACHN cells after 72 hrs by MTT assay Antiproliferative activity against human ACHN cells after 72 hrs by MTT assay	[PMID: 29787262]
AGS	IC₅₀	0.34 μM Compound: MS-275	Antiproliferative activity against human AGS cells after 72 hrs by MTT assay Antiproliferative activity against human AGS cells after 72 hrs by MTT assay	[PMID: 29787262]
AGS	IC₅₀	26.67 μM Compound: MS-275	Cytotoxicity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human AGS cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
ASPC1	GI₅₀	6.9 μM Compound: 6; MS-275	Growth inhibition of human AsPC1 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human AsPC1 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
B16-F10	IC₅₀	1.15 μM Compound: 2; MS-275	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell viability measured for 48 hrs in presence of (2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone by microplate reader based MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell viability measured for 48 hrs in presence of (2-phenylthiazol-4-yl)(3,4,5-trimethoxyphenyl)methanone by microplate reader based MTT assay	[PMID: 34097389]
B16-F10	IC₅₀	2.26 μM Compound: 2; MS-275	Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based MTT assay	[PMID: 34097389]
B16-F10	IC₅₀	9.27 μM Compound: MS-275	Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 39031090]
BGC-823	IC₅₀	26.98 μM Compound: MS-275	Cytotoxicity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human BGC-823 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
C6	IC₅₀	0.33 μM Compound: MS-275	Antiproliferative activity against rat C6 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against rat C6 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34656900]
DLD-1	IC₅₀	1.74 μM Compound: 5; MS-275	Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human DLD-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
DU-145	IC₅₀	1 μM Compound: 4 (MS-275)	Inhibitory concentration against prostate DU145 cell line Inhibitory concentration against prostate DU145 cell line	[PMID: 12593661]
DU-145	IC₅₀	2 μM Compound: MS-275	Cytotoxicity against human DU145 cells by MTT assay Cytotoxicity against human DU145 cells by MTT assay	[PMID: 19131248]
DU-145	IC₅₀	3.75 μM Compound: MS-275; 84	Cytotoxicity against human DU-145 cells Cytotoxicity against human DU-145 cells	[PMID: 33077264]
Epithelial cell	IC₅₀	> 20000 nM Compound: 4, MS-275	Antiproliferative activity against human renal epithelial cells by CellTiter-Blue cell viability assay Antiproliferative activity against human renal epithelial cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
Fibroblast	IC₅₀	20 μM Compound: MS-275	Toxicity in breast fibroblasts Toxicity in breast fibroblasts	[PMID: 18212103]
G-401	CC₅₀	1300 nM Compound: 3, MS-275, SNDX-275	Antiproliferative activity against human G401 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human G401 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
G-401	IC₅₀	1300 nM Compound: 4, MS-275	Antiproliferative activity against human G401 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human G401 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
GES1	IC₅₀	60.17 μM Compound: MS-275	Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human GES1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
HCT-116	CC₅₀	700 nM Compound: 3, MS-275, SNDX-275	Antiproliferative activity against human P53 expressing HCT116 cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53 expressing HCT116 cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
HCT-116	GI₅₀	0.6 μM Compound: MS-275, SNDX-275	Growth inhibition of human HCT116 cells after 2 days by MTT assay Growth inhibition of human HCT116 cells after 2 days by MTT assay	[PMID: 22541394]
HCT-116	IC₅₀	0.47 μM Compound: MS275	Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HCT-116	IC₅₀	0.47 μM Compound: MS275	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HCT-116	IC₅₀	0.5 μM Compound: 1g, MS-275	Inhibition of human HCT116 cells Inhibition of human HCT116 cells	[PMID: 18247554]
HCT-116	IC₅₀	0.5 μM Compound: MS-275	In vitro antiproliferative activity against human cancer cell line HCT116 using MTT assay In vitro antiproliferative activity against human cancer cell line HCT116 using MTT assay	[PMID: 14684344]
HCT-116	IC₅₀	0.56 μM Compound: MS-275	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
HCT-116	IC₅₀	0.6 μM Compound: 4 (MS-275)	Inhibitory concentration against colon HCT116 cell line Inhibitory concentration against colon HCT116 cell line	[PMID: 12593661]
HCT-116	IC₅₀	0.67 μM Compound: 3, SNDX-275	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 21742496]
HCT-116	IC₅₀	0.76 μM Compound: MS-275	Antiproliferative activity against human HCT116 cells after 3 days by WST-1 assay Antiproliferative activity against human HCT116 cells after 3 days by WST-1 assay	[PMID: 22321215]
HCT-116	IC₅₀	0.78 μM Compound: MS-275	Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human HCT116 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
HCT-116	IC₅₀	0.8 μM Compound: MS-275	Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay	[PMID: 20452226]
HCT-116	IC₅₀	0.82 μM Compound: 5; MS-275	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HCT-116	IC₅₀	1.06 μM Compound: MS-275	Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human HCT-116 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
HCT-116	IC₅₀	1.72 μM Compound: 2; MS-275	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based MTT assay	[PMID: 34097389]
HCT-116	IC₅₀	2.03 μM Compound: Entinostat	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28340413]
HCT-116	IC₅₀	2.07 μM Compound: MS275	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 28415009]
HCT-116	IC₅₀	2.3 μM Compound: MS-275	Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 39031090]
HCT-116	IC₅₀	2.48 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HCT-116 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
HCT-116	IC₅₀	27.47 μM Compound: MS-275	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 18701301]
HCT-116	IC₅₀	5.1 μM Compound: MS-275	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 26140961]
HCT-116	IC₅₀	5.4 μM Compound: MS-275	Tested for antiproliferative activity against HCT116 colorectal human carcinoma cell using WST-1 assay Tested for antiproliferative activity against HCT116 colorectal human carcinoma cell using WST-1 assay	[PMID: 11992774]
HCT-116	IC₅₀	670 nM Compound: 6, SNDX-275	Antiproliferative activity against human HCT116 cells assessed as growth inhibition Antiproliferative activity against human HCT116 cells assessed as growth inhibition	[PMID: 21650221]
HCT-116	IC₅₀	700 nM Compound: 4, MS-275	Antiproliferative activity against human HCT116 cells by CellTiter-Blue cell viability assay Antiproliferative activity against human HCT116 cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
HCT-116	IC₅₀	< 0.1 μM Compound: MS-275	Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 22705022]
HEK293	IC₅₀	120 nM Compound: 3, MS-275, SNDX-275	Inhibition of human C-terminal FLAG-tagged HDAC1 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC1 in HEK293 cells	[PMID: 19441846]
HEK293	IC₅₀	120 nM Compound: MS-275	Inhibition of HDAC1 in HEK293 cells Inhibition of HDAC1 in HEK293 cells	[PMID: 18308563]
HEK293	IC₅₀	250 nM Compound: 3, MS-275, SNDX-275	Inhibition of human C-terminal FLAG-tagged HDAC2 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC2 in HEK293 cells	[PMID: 19441846]
HEK293	IC₅₀	400 nM Compound: 3, MS-275, SNDX-275	Inhibition of human C-terminal FLAG-tagged HDAC3 in HEK293 cells Inhibition of human C-terminal FLAG-tagged HDAC3 in HEK293 cells	[PMID: 19441846]
HEK293	IC₅₀	400 nM Compound: MS-275	Inhibition of HDAC3 in HEK293 cells Inhibition of HDAC3 in HEK293 cells	[PMID: 18308563]
HEL	IC₅₀	0.44 μM Compound: MS-275	Antiproliferative activity against human HEL cells after 72 hrs by MTT assay Antiproliferative activity against human HEL cells after 72 hrs by MTT assay	[PMID: 29787262]
HEL	IC₅₀	0.48 μM Compound: MS-275	Antiproliferative activity against HEL cells after 48 hrs by MTT assay Antiproliferative activity against HEL cells after 48 hrs by MTT assay	[PMID: 28511906]
HEL	IC₅₀	1.29 μM Compound: MS275	Antiproliferative activity against HEL cells after 48 hrs by MTT assay Antiproliferative activity against HEL cells after 48 hrs by MTT assay	[PMID: 28415009]
HGC-27	IC₅₀	18.47 μM Compound: MS-275	Cytotoxicity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human HGC-27 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
HH	IC₅₀	0.49 μM Compound: 5; MS-275	Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HH cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HL-60	GI₅₀	0.214 μM Compound: Entinostat	Antiproliferative activity against human HL-60 cells incubated for 3 days by alamar blue assay Antiproliferative activity against human HL-60 cells incubated for 3 days by alamar blue assay	[PMID: 38340642]
HL-60	IC₅₀	0.37 μM Compound: 5; MS-275	Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HL-60 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HL-60	IC₅₀	1.52 μM Compound: MS275	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 28415009]
HL-60	IC₅₀	4.53 μM Compound: Entinostat	Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay Antiproliferative activity against human HL60 cells after 48 hrs by MTT assay	[PMID: 28340413]
HMEC	IC₅₀	> 37 μM Compound: 4 (MS-275)	Inhibitory concentration against normal epithelial HMEC cell line Inhibitory concentration against normal epithelial HMEC cell line	[PMID: 12593661]
HT-1080	IC₅₀	> 5 μM Compound: MS-275	Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay Antiproliferative activity against human HT1080 cells after 72 hrs by MTT assay	[PMID: 29787262]
HT-29	IC₅₀	3.1 μM Compound: MS-275	Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 29787262]
HUVEC	IC₅₀	10 μM Compound: MS-275	Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	6 μM Compound: MS-275	Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	> 100 μM Compound: Entinostat	Cytotoxicity against HUVEC after 48 hrs by MTT assay Cytotoxicity against HUVEC after 48 hrs by MTT assay	[PMID: 28340413]
HeLa	CC₅₀	1800 nM Compound: 3, MS-275, SNDX-275	Antiproliferative activity against human P53-deficient HeLa cells after 72 hrs by celltiter-blue cell viability assay Antiproliferative activity against human P53-deficient HeLa cells after 72 hrs by celltiter-blue cell viability assay	[PMID: 19441846]
HeLa	GI₅₀	19.24 μM Compound: MS-275	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 28629630]
HeLa	IC₅₀	1.33 μM Compound: MS275	Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using fluor-de-lys-green as substrate preincubated for 10 mins followed by substrate addition and measured after 30 mins by fluorescence assay	[PMID: 31003060]
HeLa	IC₅₀	1.6 μM Compound: MS275	Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
HeLa	IC₅₀	11.18 μM Compound: MS275	Inhibition of HDAC in human HeLa cells using Boc-Lys(AC)-AMC as substrate after 24 to 48 hrs by spectrofluorometry Inhibition of HDAC in human HeLa cells using Boc-Lys(AC)-AMC as substrate after 24 to 48 hrs by spectrofluorometry	[PMID: 26996372]
HeLa	IC₅₀	1190 nM Compound: MS-275	Inhibition of HDAC1/2 in human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay Inhibition of HDAC1/2 in human HeLa cell nuclear extracts pre-incubated for 5 mins before fluorogenic substrate Boc-Lys (acetyl)-AMC or Boc-Lys (triflouroacetyl)-AMC addition and measured after 30 mins by fluorescence based assay	[PMID: 32267687]
HeLa	IC₅₀	1800 nM Compound: 4, MS-275	Antiproliferative activity against human HeLa cells by CellTiter-Blue cell viability assay Antiproliferative activity against human HeLa cells by CellTiter-Blue cell viability assay	[PMID: 18370373]
HeLa	IC₅₀	1800 nM Compound: MS-275	Inhibition of HeLa cell proliferation Inhibition of HeLa cell proliferation	[PMID: 16987657]
HeLa	IC₅₀	2.36 μM Compound: MS275	Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HeLa cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
HeLa	IC₅₀	3.2 μM Compound: MS-275	Inhibition of human HDAC in HeLa cells after 30 mins by Fluor de Lys fluorescence assay Inhibition of human HDAC in HeLa cells after 30 mins by Fluor de Lys fluorescence assay	[PMID: 21889343]
HeLa	IC₅₀	3160 nM Compound: MS-275	Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay Inhibition of HDAC in human Hela cell lysate using Fluor-de-Lys as substrate compound pretreated for 30 mins before substrate addition by fluorescence assay	[PMID: 23089527]
HeLa	IC₅₀	4.8 μM Compound: 80, MS-27580	Inhibition of HDAC from human HeLa cells assessed as of histone H3 acetylation Inhibition of HDAC from human HeLa cells assessed as of histone H3 acetylation	[PMID: 19534534]
HeLa	IC₅₀	8.02 μM Compound: MS-275	Inhibition of HDAC in human HeLa cells using fluor de Lys as substrate incubated for 20 mins by microplate spectrofluorometric analysis Inhibition of HDAC in human HeLa cells using fluor de Lys as substrate incubated for 20 mins by microplate spectrofluorometric analysis	[PMID: 27060764]
HeLa	IC₅₀	< 0.1 μM Compound: MS-275	Inhibition of HDAC1 in human HeLa cell lysate using KI-104 as substrate after 40 mins by fluorescence analysis Inhibition of HDAC1 in human HeLa cell lysate using KI-104 as substrate after 40 mins by fluorescence analysis	[PMID: 22705022]
HeLa	IC₅₀	< 0.1 μM Compound: MS-275	Inhibition of HDAC2 in human HeLa cell lysate using KI-104 as substrate after 40 mins by fluorescence analysis Inhibition of HDAC2 in human HeLa cell lysate using KI-104 as substrate after 40 mins by fluorescence analysis	[PMID: 22705022]
HeLa	IC₅₀	> 1000 nM Compound: 6; MS-275	Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Lys(Ac)-pNA as substrate after 30 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract using Ac-Lys(Ac)-pNA as substrate after 30 mins by fluorescence assay	[PMID: 28395150]
HeLa	IC₅₀	> 4 μM Compound: 5; MS-275	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
HeLa	IC₅₀	> 5 μM Compound: MS-275	Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay	[PMID: 29787262]
HepG2	IC₅₀	0.9 nM Compound: 1g, MS-275	Inhibition of human HepG2 cells Inhibition of human HepG2 cells	[PMID: 18247554]
HepG2	IC₅₀	1.57 μM Compound: MS-275	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 39031090]
HepG2	IC₅₀	1.76 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
HepG2	IC₅₀	4.54 μM Compound: 5; MS-275	Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32325365]
HepG2	IC₅₀	60.12 μM Compound: MS-275	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 18701301]
Hs-578T	IC₅₀	1 μM Compound: 69	Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 24 hrs by ALDEFLUOR assay Anticancer activity against human Hs-578T cells assessed as cell growth inhibition incubated for 24 hrs by ALDEFLUOR assay	[PMID: 33650861]
HuT78	IC₅₀	> 1 μM Compound: 5; MS-275	Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human HuT78 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
Huh-7	CC₅₀	5.1 μM Compound: 9, MS-275, SNDX-275	Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay Cytotoxicity against human HuH7 cells assessed as inhibition of cell viability after 3 days by CellTiter 96 assay	[PMID: 25490700]
Huh-7	EC₅₀	1.4 μM Compound: 9, MS-275, SNDX-275	Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay Antiviral activity against HCV genotype 1b infected in human Huh7 cells after 3 days by luciferase reporter gene assay	[PMID: 25490700]
Jurkat	IC₅₀	0.25 μM Compound: MS-275	Antiproliferative activity against human Jurkat T cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay Antiproliferative activity against human Jurkat T cells assessed as reduction in cell viability measured for 48 hrs by CCK-8 assay	[PMID: 39031090]
Jurkat	IC₅₀	0.28 μM Compound: MS-275	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
Jurkat	IC₅₀	0.69 μM Compound: 2; MS-275	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based CCK-8 assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell viability measured for 48 hrs by microplate reader based CCK-8 assay	[PMID: 34097389]
K562	GI₅₀	9.32 μM Compound: MS-275	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28629630]
K562	IC₅₀	0.57 μM Compound: MS-275	Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay Antiproliferative activity against human K562 cells incubated for 72 hrs by CellTiter-Glo luminescent cell viability assay	[PMID: 36549114]
K562	IC₅₀	0.79 μM Compound: MS-275	Inhibition of KDAC3 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method Inhibition of KDAC3 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	[PMID: 26681404]
K562	IC₅₀	1.19 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay Antiproliferative activity against human K562 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
K562	IC₅₀	1.32 μM Compound: MS-275	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28511906]
K562	IC₅₀	1.48 μM Compound: MS-275	Inhibition of KDAC1 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method Inhibition of KDAC1 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	[PMID: 26681404]
K562	IC₅₀	1.68 μM Compound: MS275	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 28415009]
K562	IC₅₀	2 μM Compound: MS 27-275	Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) prepared from K562 erythroleukemia cells. Inhibition of human histone deacetylase (mixture of HDAC1 and HDAC2) prepared from K562 erythroleukemia cells.	[PMID: 12419380]
K562	IC₅₀	21.3 μM Compound: MS-275; 84	Cytotoxicity against human K562 cells Cytotoxicity against human K562 cells	[PMID: 33077264]
K562	IC₅₀	3.66 μM Compound: MS-275	Antiproliferative activity against human K562 cells after 72 hrs by MTT assay Antiproliferative activity against human K562 cells after 72 hrs by MTT assay	[PMID: 29787262]
K562	IC₅₀	4.8 μM Compound: 1	Inhibitory activity against partially purified histone deacetylase of human leukemia K562 cells. Inhibitory activity against partially purified histone deacetylase of human leukemia K562 cells.	[PMID: 10425110]
K562	IC₅₀	> 30 μM Compound: MS-275	Inhibition of KDAC6 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method Inhibition of KDAC6 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	[PMID: 26681404]
K562	IC₅₀	> 30 μM Compound: MS-275	Inhibition of KDAC8 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method Inhibition of KDAC8 in human K562 cells using [3H]acetylated histone as substrate incubated for 10 mins by liquid scintillation counting method	[PMID: 26681404]
KB	GI₅₀	6.632 μM Compound: 8; MS-275	Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay Antiproliferative activity against human KB cells incubated for 48 hrs by SRB assay	[PMID: 32171161]
KB	IC₅₀	520 nM Compound: 6; MS-275	Growth inhibition of human KB cells after 48 hrs by SRB assay Growth inhibition of human KB cells after 48 hrs by SRB assay	[PMID: 30476825]
KG-1	IC₅₀	0.42 μM Compound: 5; MS-275	Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
KG-1	IC₅₀	> 5 μM Compound: MS-275	Antiproliferative activity against human KG1 cells after 72 hrs by MTT assay Antiproliferative activity against human KG1 cells after 72 hrs by MTT assay	[PMID: 29787262]
KM3/BTZ	IC₅₀	2040 nM Compound: MS-275	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells incubated for 48 hrs by MTT assay	[PMID: 32267687]
KM3/BTZ	IC₅₀	98 nM Compound: MS-275	Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay Antiproliferative activity against bortezomib resistant human KM3/BTZ cells in presence of bortezomib incubated for 48 hrs by MTT assay	[PMID: 32267687]
LN-18	GI₅₀	0.917 μM Compound: Entinostat	Antiproliferative activity against human LN-18 cells incubated for 3 days by alamar blue assay Antiproliferative activity against human LN-18 cells incubated for 3 days by alamar blue assay	[PMID: 38340642]
LNCaP	IC₅₀	0.36 μM Compound: 4, MS-275	Antiproliferative activity against human LNCap by MTT assay Antiproliferative activity against human LNCap by MTT assay	[PMID: 18166465]
MCF7	GI₅₀	19.26 μM Compound: MS-275	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28629630]
MCF7	IC₅₀	0.35 μM Compound: 10; MS-275	Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay Antiproliferative activity against human MCF7 cells treated for 48 hrs followed by refreshed every 96 hrs measured on day 10 by Lowry assay	[PMID: 26613635]
MCF7	IC₅₀	4.02 μM Compound: Entinostat	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28340413]
MCF7	IC₅₀	4.3 μM Compound: 1g, MS-275	Inhibition of human MCF7 cells Inhibition of human MCF7 cells	[PMID: 18247554]
MCF7	IC₅₀	5 μM Compound: 4 (MS-275)	Inhibitory concentration against breast MCF-7 cell line Inhibitory concentration against breast MCF-7 cell line	[PMID: 12593661]
MCF7	IC₅₀	6.96 μM Compound: MS-275	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured for 48 hrs by MTT assay	[PMID: 39031090]
MCF7	IC₅₀	7.881 μM Compound: MS-275	Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay	[PMID: 26140961]
MDA-MB-231	GI₅₀	1.41 μM Compound: 6; MS-275	Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human MDA-MB-231 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
MDA-MB-231	IC₅₀	1 μM Compound: 69	Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by ALDEFLUOR assay Anticancer activity against human MDA-MB-231 cells assessed as cell growth inhibition incubated for 24 hrs by ALDEFLUOR assay	[PMID: 33650861]
MDA-MB-231	IC₅₀	2.55 μM Compound: MS-275	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 29787262]
MDA-MB-231	IC₅₀	2.6 μM Compound: 5; MS-275	Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 32325365]
MDA-MB-231	IC₅₀	2.63 μM Compound: 5; MS-275	Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
MDA-MB-231	IC₅₀	3 μM Compound: 4 (MS-275)	Inhibitory concentration against breast MDA-MB-231 cell line Inhibitory concentration against breast MDA-MB-231 cell line	[PMID: 12593661]
MDA-MB-231	IC₅₀	4.63 μM Compound: MS-275	Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
MDA-MB-231	IC₅₀	4.63 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
MDA-MB-468	IC₅₀	2.73 μM Compound: 5; MS-275	Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
MGC-803	IC₅₀	4.89 μM Compound: MS275	Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human MGC803 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
MGC-803	IC₅₀	58.55 μM Compound: MS-275	Cytotoxicity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human MGC-803 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
MKN-45	IC₅₀	1200 nM Compound: 6; MS-275	Growth inhibition of human MKN45 cells after 48 hrs by SRB assay Growth inhibition of human MKN45 cells after 48 hrs by SRB assay	[PMID: 30476825]
MKN-45	IC₅₀	4.16 μM Compound: 1g, MS-275	Antiproliferative activity against human MKN45 cells Antiproliferative activity against human MKN45 cells	[PMID: 18247554]
MKN-45	IC₅₀	4.16 μM Compound: MS-275 (4)	Compound was tested for antiproliferative activity against human MKN45 cancer cell lines Compound was tested for antiproliferative activity against human MKN45 cancer cell lines	[PMID: 14667227]
MOLT-4	IC₅₀	0.45 μM Compound: MS-275	Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 72 hrs by MTT assay	[PMID: 29787262]
MOLT-4	IC₅₀	0.65 μM Compound: MS-275	Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay Antiproliferative activity against human MOLT4 cells after 48 hrs by MTT assay	[PMID: 28511906]
MV4-11	EC₅₀	806.2 nM Compound: Ent; MS275	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability after 48 hrs by CellTiter-Blue dye based spectrophotometric analysis	[PMID: 32321249]
MV4-11	EC₅₀	< 30 nM Compound: entinostat	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 48 hrs by Cell-titer-blue cell viability assay	[PMID: 27754681]
MV4-11	IC₅₀	0.24 μM Compound: 11; MS-275	Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as cell viability after 72 hrs by CCK8 assay	[PMID: 33077265]
MV4-11	IC₅₀	0.24 μM Compound: MS-275	Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay Cytotoxicity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by cell-titer blue assay	[PMID: 38964169]
MV4-11	IC₅₀	0.71 μM Compound: MS275	Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter-blue viability assay Cytotoxicity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter-blue viability assay	[PMID: 38060537]
NCI-H1299	IC₅₀	6.74 μM Compound: MS275	Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
NCI-H1299	IC₅₀	> 2 μM Compound: 5; MS-275	Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
NCI-H1299	IC₅₀	> 4000 nM Compound: 6, SNDX-275	Antiproliferative activity against human H1299 cells Antiproliferative activity against human H1299 cells	[PMID: 21650221]
NCI-H446	IC₅₀	1 μM Compound: 4 (MS-275)	Inhibitory concentration against lung H446 cell line Inhibitory concentration against lung H446 cell line	[PMID: 12593661]
NCI-H661	IC₅₀	2.19 μM Compound: Entinostat	Antiproliferative activity against human NCI-H661 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H661 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
NCI-H661	IC₅₀	2.19 μM Compound: MS-275	Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human NCI-H661 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
NCI-H661	IC₅₀	> 2 μM Compound: 5; MS-275	Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay Cytotoxicity against human NCI-H661 cells assessed as reduction in cell viability incubated for 72 hrs by MTS assay	[PMID: 33588178]
NIH3T3	IC₅₀	2.42 μM Compound: MS275	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	[PMID: 31003060]
PC-3	GI₅₀	0.087 μM Compound: Entinostat	Antiproliferative activity against human PC-3 cells incubated for 3 days by alamar blue assay Antiproliferative activity against human PC-3 cells incubated for 3 days by alamar blue assay	[PMID: 38340642]
PC-3	GI₅₀	0.43 μM Compound: 6; MS-275	Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay Growth inhibition of human PC3 cells after 48 hrs by sulforhodamine B assay	[PMID: 28395150]
PC-3	GI₅₀	19.09 μM Compound: MS-275	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28629630]
PC-3	IC₅₀	4.89 μM Compound: MS-275	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28511906]
PC-3	IC₅₀	59.06 μM Compound: MS-275	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 18701301]
PC-3	IC₅₀	6.36 μM Compound: Entinostat	Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay	[PMID: 28340413]
PC-3	IC₅₀	> 5 μM Compound: MS-275	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 29787262]
PrEC	GI₅₀	2.23 μM Compound: Entinostat	Cytotoxicity against human PrEC cells incubated for 3 days by alamar blue assay Cytotoxicity against human PrEC cells incubated for 3 days by alamar blue assay	[PMID: 38340642]
RS4-11	IC₅₀	0.3 μM Compound: MS275	Cytotoxicity against human RS4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter-blue viability assay Cytotoxicity against human RS4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by celltiter-blue viability assay	[PMID: 38060537]
S2	IC₅₀	940 nM Compound: 6, MS-275	Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells Inhibition of Plasmodium falciparum HDAC1 expressed in Drosophila melanogaster S2 cells	[PMID: 19317450]
SGC-7901	IC₅₀	0.98 μM Compound: MS-275; SNDX-275	Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay Antiproliferative activity against human SGC-7901 cells measured after 48 hrs by MTT assay	[PMID: 35041998]
SGC-7901	IC₅₀	> 200 μM Compound: MS-275	Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay Cytotoxicity against human SGC-7901 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay	[PMID: 34628244]
SK-BR-3	IC₅₀	0.87 μM Compound: 1g, MS-275	Antiproliferative activity against human SKBR3 cells Antiproliferative activity against human SKBR3 cells	[PMID: 18247554]
SK-BR-3	IC₅₀	0.87 μM Compound: MS-275 (4)	Compound was tested for antiproliferative activity against human SK-BR-3 cancer cell lines Compound was tested for antiproliferative activity against human SK-BR-3 cancer cell lines	[PMID: 14667227]
SKM-1	IC₅₀	389 nM Compound: MS-275	Cytotoxicity against human SKM-1 cells assessed as viable cells incubated for 72 hrs by CCK8 assay Cytotoxicity against human SKM-1 cells assessed as viable cells incubated for 72 hrs by CCK8 assay	[PMID: 37184921]
SMMC-7721	IC₅₀	5.97 μM Compound: MS275	Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells after 72 hrs by CCK-8 assay	[PMID: 29202397]
SMMC-7721	IC₅₀	5.97 μM Compound: MS275	Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell growth incubated for 72 hrs by CCK-8 assay	[PMID: 31003060]
SNU-16	IC₅₀	2194.59 nM Compound: MS-275 (4)	Inhibitory activity against Histone deacetylase (HDAC) from SNU-16 (human gastric adenocarcinoma) cells Inhibitory activity against Histone deacetylase (HDAC) from SNU-16 (human gastric adenocarcinoma) cells	[PMID: 14667227]
SNU-16	IC₅₀	233 nM Compound: 1g, MS-275	Inhibition of HDAC from human SNU16 cells Inhibition of HDAC from human SNU16 cells	[PMID: 18247554]
SW-620	IC₅₀	3.2 μM Compound: 1g, MS-275	Inhibition of human SW620 cells Inhibition of human SW620 cells	[PMID: 18247554]
SW48	IC₅₀	5 μM Compound: 4 (MS-275)	Inhibitory concentration against colon SW48 cell line Inhibitory concentration against colon SW48 cell line	[PMID: 12593661]
Sf9	IC₅₀	0.118 μM Compound: MS-275	Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.247 μM Compound: MS-275	Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.505 μM Compound: Entinostat	Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay Inhibition of recombinant human full length C-terminal FLAG-tagged HDAC2 expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	0.519 μM Compound: Entinostat	Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate incubated for 90 mins by fluorescence assay Inhibition of recombinant human full length C-terminal His/FLAG-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using ZMAL as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	2.85 μM Compound: Entinostat	Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay Inhibition of human recombinant full length C-terminal His-tagged HDAC3 (1 to 428 residues)/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using Boc-Lys(epsilon-acetyl)-AMC as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	77.18 nM Compound: Ent; MS275	Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis Inhibition of recombinant human C-terminal GST/His-tagged HDAC3 (1 to 428 residues) co-expressed with human N-terminal GST-tagged NCOR2 (395 to 489 residues) in baculovirus infected Sf9 cells using Boc-Lys(acetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	[PMID: 32321249]
Sf9	IC₅₀	9.32 μM Compound: 2; MS-275	Inhibition of full length N-terminal GST-tagged human recombinant HDAC6 (1 to 1215 residues) expressed in Baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys (Ac)-AMC as substrate pretreated for 5 mins followed by substrate addition and measured after 30 mins Inhibition of full length N-terminal GST-tagged human recombinant HDAC6 (1 to 1215 residues) expressed in Baculovirus infected Sf9 cells using Ac-Leu-Gly-Lys (Ac)-AMC as substrate pretreated for 5 mins followed by substrate addition and measured after 30 mins	[PMID: 34097389]
Sf9	IC₅₀	> 1 μM Compound: MS-275	Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	> 1 μM Compound: MS-275	Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	> 1 μM Compound: MS-275	Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	> 1 μM Compound: MS-275	Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	> 1 μM Compound: MS-275	Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	> 10 μM Compound: Entinostat	Inhibition of human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells ZMAL as substrate incubated for 90 mins by fluorescence assay Inhibition of human full length N-terminal GST-tagged HDAC6 expressed in baculovirus infected Sf9 insect cells ZMAL as substrate incubated for 90 mins by fluorescence assay	[PMID: 31762274]
Sf9	IC₅₀	> 10000 nM Compound: Ent; MS275	Inhibition of recombinant full length human C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis Inhibition of recombinant full length human C-terminal His-tagged HDAC8 expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	[PMID: 32321249]
Sf9	IC₅₀	> 10000 nM Compound: Ent; MS275	Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis Inhibition of recombinant human C-terminal His-tagged HDAC9 (604 to 1066 residues) expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	[PMID: 32321249]
Sf9	IC₅₀	> 10000 nM Compound: Ent; MS275	Inhibition of recombinant human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis Inhibition of recombinant human N-terminal GST-tagged HDAC7 (518 to end residues) expressed in baculovirus infected Sf9 cells using Boc-Lys (trifluoroacetyl)-AMC as substrate preincubated for 1 hr followed by substrate addition and measured after 2 hrs by fluorescence based micro plate reader analysis	[PMID: 32321249]
T-24	IC₅₀	2.5 μM Compound: 4 (MS-275)	Inhibitory concentration against bladder T24 cell line Inhibitory concentration against bladder T24 cell line	[PMID: 12593661]
THP-1	IC₅₀	2.3 μM Compound: MS-275	Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay Antiproliferative activity against human THP-1 cells assessed as inhibition of cell growth measured after 72 hrs by MTS assay	[PMID: 39089850]
U-251	GI₅₀	6.5 μM Compound: MS-275, SNDX-275	Growth inhibition of human U251 cells after 2 days by MTT assay Growth inhibition of human U251 cells after 2 days by MTT assay	[PMID: 22541394]
U-251	IC₅₀	> 30 μM Compound: MS-275	Antiproliferative activity against human U-251 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human U-251 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34656900]
U-266	IC₅₀	6.1 μM Compound: MS275	Antiproliferative activity against human U266 cells after 48 hrs by MTT assay Antiproliferative activity against human U266 cells after 48 hrs by MTT assay	[PMID: 28415009]
U-87MG ATCC	IC₅₀	4.34 μM Compound: MS-275	Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay Antiproliferative activity against human U-87 MG cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay	[PMID: 34656900]
U-937	IC₅₀	0.3 μM Compound: MS-275	Inhibition of human HDAC1 in U937 cells by immunoprecipitation assay Inhibition of human HDAC1 in U937 cells by immunoprecipitation assay	[PMID: 18381238]
U-937	IC₅₀	0.55 μM Compound: Entinostat	Antiproliferative activity against human U937 cells incubated for 72 hrs by MTT assay Antiproliferative activity against human U937 cells incubated for 72 hrs by MTT assay	[PMID: 25953722]
U-937	IC₅₀	0.55 μM Compound: MS-275	Antiproliferative activity against human U937 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay Antiproliferative activity against human U937 cells assessed as inhibition of cell growth after 72 hrs by MTT-based assay	[PMID: 25874326]
U-937	IC₅₀	0.77 μM Compound: MS275	Antiproliferative activity against human U937 cells after 48 hrs by MTT assay Antiproliferative activity against human U937 cells after 48 hrs by MTT assay	[PMID: 28415009]
U-937	IC₅₀	142 μM Compound: MS-275	Inhibition of human HDAC4 in U937 cells by immunoprecipitation assay Inhibition of human HDAC4 in U937 cells by immunoprecipitation assay	[PMID: 18381238]
WI-38	IC₅₀	> 20 μM Compound: MS-275	Toxicity in human WI38 cells Toxicity in human WI38 cells	[PMID: 18212103]

In Vitro

Binding affinity of Entinostat (MS-275) against HDAC1 and HDAC2 is 282 nM and 156 nM, respectively^[1]. Effects of the HDAC inhibitor Entinostat (MS-275) have been examined in human leukemia and lymphoma cells (U937, HL-60, K562, and Jurkat) as well as in primary acute myelogenous leukemia blasts in relation to differentiation and apoptosis. MS-275 displays dose-dependent effects in each of the cell lines. When administered at a low concentration (e.g., 1 μM), MS-275 exhibits potent antiproliferative activity, inducing p21CIP1/WAF1-mediated growth arrest and expression of differentiation markers (CD11b) in U937 cells. Entinostat (MS-275) potently induces cell death, triggering apoptosis in ~70% of cells at 48 h^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Solvant et solubilité

In Vitro:

DMSO : 50 mg/mL (132.83 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.6567 mL	13.2834 mL	26.5668 mL
5 mM	0.5313 mL	2.6567 mL	5.3134 mL
10 mM	0.2657 mL	1.3283 mL	2.6567 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (6.64 mM); Clear solution
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Pureté et documentation

Purity: 99.98%

Fiche technique (280 KB) SDS (644 KB)

COA (245 KB) RP-HPLC (260 KB) MS (68 KB) Elemental Analysis Report (103 KB)

Instruction de manipulation (2659 KB)

Références

[1]. Lauffer BE, et al. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem. 2013 Sep 13;288(37):26926-43. [Content Brief]

[2]. Rosato RR, et al. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res. 2003 Jul 1;63(13):36 [Content Brief]

[3]. Saito A, et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A, 1999, 96(8), 4592-4597. [Content Brief]

[4]. Zhang ZY, et al. MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neurosci, 2010, 169, 370-377. [Content Brief]

Si può anche essere interessati nei seguenti prodotti:

Cat#

Descrizione

Cond.

Priced

NB-64-110138-5mg

Melphalan [148-82-3]

5mg

Entinostat [209783-80-2]

Cat# HY-12163-5mg

Marca : MedChemExpress

Entinostat Related Antibodies

Si può anche essere interessati nei seguenti prodotti: